VITREOUS CAVITY PENETRATION OF CEFTAZIDIME AFTER INTRAVENOUS ADMINISTRATION

被引：41

作者：

AGUILAR, HE ^{[1
]}

MEREDITH, TA ^{[1
]}

SHAARAWY, A ^{[1
]}

KINCAID, M ^{[1
]}

DICK, J ^{[1
]}

机构：

[1] ST LOUIS UNIV,SCH MED,DEPT OPHTHALMOL,ST LOUIS,MO

来源：

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES | 1995年 / 15卷 / 02期

关键词：

CEFTAZIDIME; VITREOUS; ANTIBIOTIC; GRAM-NEGATIVE ENDOPHTHALMITIS;

D O I：

10.1097/00006982-199515020-00012

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Purpose: Penetration of ceftazidime, a third generation cephalosporin, into the vitreous cavity after intravenous administration was investigated. Methods: Because antimicrobial penetration varies with surgical status of the eye and with inflammation, studies were conducted in phakic, aphakic, and aphakic, vitrectomized eyes in both normal and inflamed conditions. Ceftazidime 50 mg/kg was administered every 8 hours and vitreous cavity concentrations were tested at intervals from 2 to 72 hours after the initial dose. Results: No penetration was found into control phakic and aphakic eyes, but drug concentrations were detected in inflamed eyes at 24 hours. Vitreous concentrations of ceftazidime in aphakic, vitrectomized eyes reached levels well above the minimal inhibitory concentration (MIC) for Pseudomonas organisms within 2 hours of intravenous administration in control eyes (8.5 mu g/ml) and inflamed eyes (35.4 mu g/ml). Inflammation and removal of the lens and vitreous significantly enhanced ceftazidime penetration at all time periods tested. Conclusion: Ceftazidime penetrates into the vitreous cavity of inflamed eyes after intravenous administration and achieves concentrations above the MIC for Pseudomonas organisms. Penetration is greatest in aphakic, vitrectomized eyes.

引用

页码：154 / 159

页数：6

共 21 条

[1]

Donowitz G.R., Third generation cephalosporins, Infect Dis Clin North Am, 3, pp. 595-612, (1989)

[2]

Donowitz G.R., Mandel G.L., Cephalosporins, (1990)

[3]

Campochiaro P.A., Green W.R., Toxicity of intravitreal ceftazidime in primate retina, Arch Ophthalmol, 110, pp. 1625-1629, (1992)

[4]

Smith M.A., Sorenson J.A., Lowy F.D., Treatment of experimental methicillin-resistant staphylococcus epidermidis endophthalmitis with intravitreal vancomycin, Ophthalmology, 93, pp. 1328-1335, (1989)

[5]

Flynn H.W., Pulido J.S., Pflugfelder S.C., Endophthalmitis therapy: Changing antibiotic sensitivity patterns and current therapeutic recommendations, Arch Ophthalmol, 109, (1991)

[6]

Barza M., Kane A., Baum J., Comparison of the effects of continuous and intermittent systemic administration on the penetration of gentamicin into infected rabbit eyes, J Infect Dis, 147, pp. 144-148, (1983)

[7]

Rubinstein E., Goldfarb J., Keren G., Et al., The penetration of gentamiein into the vitreous humor in man, Invest Ophthalmol Vis Sci, 24, pp. 637-639, (1983)

[8]

Yoshizumi M.O., Leinwand M.J., Kim J., Topical and intravenous gentamiein in traumatically lacerated eyes, Graefes Arch Clin Exp Ophthalmol, 230, pp. 175-177, (1992)

[9]

Irvine W.D., Flynn H.W., Miller D., Pflugfelder S.C., Endophthalmitis caused by gram-negative organisms, Arch Ophthalmol, 110, pp. 1450-1454, (1992)

[10]

Donahue S., Kowalski R., Eller A., Et al., Empiric treatment of endophthalmitis, Arch Ophthalmol, 112, pp. 45-53, (1994)

← 1 2 3 →